Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Xu H, Kaye JA, Saltus CW, Crawford J, Gasa E, Goodnough LT. Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents. Expert Rev Hematol. 2014 Oct;7(5):617-33. doi: 10.1586/17474086.2014.943730
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
McKenna SP, Williamson T, Renck-Hooper U, Whalley D. The development and testing of UK and Canadian English versions of the Incontinence Quality of Life Index (IQoLI). J Outcomes Res. 1997;1:9-18.
Renck-Hooper U, McKenna SP, Whalley D. Measuring quality of life in female urinary urge incontinence: development and psychometric properties of the IQoLI. J Outcomes Res. 1997;1:1-8.
Walker AW, Loughlin JE, Friedlander ER, Rothman KJ, Dreyer NA. Projections of asbestos-related disease, 1980-2009. J Occup Med. 1983 May;25(5):409-25.